48.1 F
New York
Monday, November 30, 2020

Gilead Sciences [NASDAQ: GILD] Announces Agreement With Jounce [NASDAQ: JNCE]

Must read

Tesla [NASDAQ: TSLA] Recalls 9537 SUV’s Because Of Manufacturing Issues

Tesla Inc. has released safety recall orders for more than 9500 of its vehicle in the United States. The vehicles include Model Xs...

Northrop [NYSE:NOC] awarded a deal of $4.8B for Global Hawk Aircraft

Northrop Gruman Corp. has been awarded a deal to perform development, transformation, retrofit, and sustenance activities for the Global Hawk Program. This deal...

Athene Enters Into An Agreement With Hertz To Buy Donlen Corp.

Athene Holdings ltd. entered into a deal to buy Donlen corporation from Hertz Global Holdings Inc. Hertz's fully own Donlen Corporation. The stock...

Verizon [NYSE: VZ] Announced to acquire Tracfone for $6.25 billion.

Verizon Communication Inc. declared that it penned down a deal with America Movil to purchase Tracfone for $6.25B. The companies came to terms...

Gilead Sciences, Inc. [NASDAQ: GILD] announced Tuesday it has signed a new deal with Jounce Therapeutics, Inc. [NASDAQ: JNCE] for a novel Immunotherapy program. The purpose of the deal is to license the JTX-1811 program.

Gilead Sciences will have exclusive rights to develop and commercialize Anti-CCR8 antibodies. JTX-1811 is a monoclonal antibody developed to selectively destroy immunosuppressive tumor-infiltrating T regulatory (TITR) cells.

Shares of Gilead Sciences traded down 1.00% after losing -0.67 on Tuesday. It has a day low range of 66.06 and a day high range of 66.47.

Gilead Sciences Inc last closed at $66.08, in a 52-week range of $60.89 to $85.97. It has traded up 8.52% from its 52-weeks low and traded down -23.14% from its 52-weeks high.

Let’s take a quick look at its profitability, it has a return on assets (ROA) of -0.40%, return on equity (ROE) of -1.20%, and return on investment (ROI) of 9.50%.

Furthermore, Gilead Sciences has a Gross Margin of 78.60%, a Profit Margin of -1.20%, and an Operating Margin of -4.30%.

Gilead Sciences (GILD) has a current ratio of 2.30. Moreover, its quick ratio is 2.20. The market cap of GILD has remained high, hitting $84.06 billion at the time of writing.

Now looking at the share price of Jounce Therapeutics soared 70.04%, as it gained +3.39 on Tuesday. It has a day low and high range of $7.10 and $8.50, respectively.

The share price of Jounce Therapeutics went from a low point around $2.79 to briefly over $10.00 in the past 52 weeks, though shares have since pulled back to $8.23. JNCE market cap has remained high, hitting $157.59 million at the time of writing.

Turing our focus on its profitability, its return on assets (ROA), return on equity (ROE), and return on investment (ROI) is 11.30%, 13.50%, and 30.20%. Furthermore, its Profit Margin is 18.20%.

If we look at the terms of the Agreement, will pays an upfront payment of $85 million to, and a $35 million equity investment at a premium in, Jounce upon closing.

Additionally, Jounce may get up to an additional $685 million in future clinical, regulatory, and commercial milestone payments.

Jounce will lead the development of JTX-1811 through IND clearance, after that Gilead Sciences will have exclusive rights to develop JTX-1811. The deal is expected to close in the second half of 2020.

More articles

Latest article

ViacomCBS [NASDAQ: VIAC] Agreed To Sell Simon And Schuster For $2.175 Billion In Cash

ViacomCBS Inc. declared that it entered into an agreement with Penguin Random House LCC to sell Simon and Schuster. It will be sold...

IBM [NYSE: IBM] Plans To Cut Down 20% Of Its Workforce

International business machines Corp. declared that the company is preparing to cut down 10,000 jobs in Europe which makes it’s 20% of the...

Ford [NYSE: F ] Booked Ultra-Cold Freezers To Ensure Autoworkers Access To The Covid-19 Vaccine

Ford Motors Co. revealed recently that to stock Pfizer Inc Covid-19 vaccine securely, it has requested 12 of the ultra-cold freezer. The automaker...

Transdigm [NYSE: TDG] Enters Into An Agreement To Buy Cobham Aero Connectivity

Transdigm group incorporation , the global aircraft component manufacturer and provider declared the acquisition of Cobham Aero Connectivity, the top supplier of antennas and...

LCI Industries’ [NYSE: LCII] Subsidiary Lippert Components Acquires Challenger Door

LCI Industries has revealed that its unit Lippert Components has completed the acquisition of Challenger Door, Inc. This acquisition will provide the opportunity...

Blackstone Group [NYSE: BX] Finalizes Recapitalization Of BioMed Realty

The Blackstone Group Inc. has disclosed today that Blackstone Real Estate Partners VIII L.P.  has executed the deal related to BioMed Realty. The...

Pfizer-BioNTech’s COVID19 Vaccine Candidate Acheive 95% Success

Pfizer Inc. (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) have disclosed Wednesday that their COVID-19 vaccine candidate, BNT162b2, has shown a 95% efficacy rate...

Scienjoy [NASDAQ: SJ] Inks Agreement With China Mobile

Scienjoy Holdings Corporation has revealed today that it has inked a cooperative agreement with China Mobile on November 1, 2020. The company disclosed...